양세훈 교수 연구실
article|
인용수 17
·2021
Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
Sung Yong Lee, Chang‐Min Choi, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong‐Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Ji Young Park, Young‐Chul Kim, In‐Jae Oh, Chi Young Jung, Sang Hoon Lee, Seong Hoon Yoon, Juwhan Choi, Tae Won Jang
IF 4.726Translational Lung Cancer Research
초록
Afatinib was well tolerated with no new safety signals, and efficacy was encouraging in Korean patients with <i>EGFR</i>m<sup>+</sup> NSCLC, including those with baseline brain metastases and/or uncommon <i>EGFR</i> mutations. AE management with dose reductions facilitated a long TTD, prolonging the chemotherapy-free period for many patients.
키워드
AfatinibMedicineDiscontinuationRashInternal medicineT790MLung cancerAdverse effectOncologyOsimertinib